Stephen Willey
Stock Analyst at Stifel
(4.15)
# 767
Out of 5,182 analysts
135
Total ratings
48.48%
Success rate
16.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Buy | $120 → $123 | $97.74 | +25.84% | 9 | Apr 29, 2026 | |
| CELC Celcuity | Maintains: Buy | $115 → $125 | $120.07 | +4.11% | 3 | Mar 26, 2026 | |
| INSM Insmed | Maintains: Buy | $205 → $208 | $134.94 | +54.14% | 9 | Mar 24, 2026 | |
| ZYME Zymeworks | Maintains: Buy | $40 → $47 | $27.94 | +68.22% | 8 | Mar 3, 2026 | |
| ACLX Arcellx | Downgrades: Hold | $127 → $115 | $115.07 | -0.06% | 2 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $125 → $110 | $67.26 | +63.54% | 2 | Feb 17, 2026 | |
| EXEL Exelixis | Maintains: Hold | $43 → $44 | $44.93 | -2.07% | 20 | Feb 11, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $33 → $35 | $17.08 | +104.92% | 6 | Jan 29, 2026 | |
| NKTX Nkarta | Maintains: Buy | $12 → $11 | $2.77 | +297.11% | 5 | Nov 11, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $30 → $9 | $4.12 | +118.45% | 3 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $4.16 | +68.27% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $23.96 | +16.86% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $5 | $3.01 | +66.11% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $20 | $4.84 | +313.22% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.38 | +595.41% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.51 | +164.90% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $21.92 | +114.42% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $120 | $12.46 | +863.47% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $2.73 | +46.52% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $54.53 | +13.70% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.84 | +389.13% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.40 | +757.14% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.15 | +24,943.48% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.67 | +686.52% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $1.66 | +140.96% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $302.11 | -59.29% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $71.78 | -34.52% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $53.30 | +104.50% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $23.69 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $7.93 | +190.04% | 5 | Feb 7, 2018 |
Incyte
Apr 29, 2026
Maintains: Buy
Price Target: $120 → $123
Current: $97.74
Upside: +25.84%
Celcuity
Mar 26, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $120.07
Upside: +4.11%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $205 → $208
Current: $134.94
Upside: +54.14%
Zymeworks
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $47
Current: $27.94
Upside: +68.22%
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $127 → $115
Current: $115.07
Upside: -0.06%
Disc Medicine
Feb 17, 2026
Maintains: Buy
Price Target: $125 → $110
Current: $67.26
Upside: +63.54%
Exelixis
Feb 11, 2026
Maintains: Hold
Price Target: $43 → $44
Current: $44.93
Upside: -2.07%
Nurix Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $17.08
Upside: +104.92%
Nkarta
Nov 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.77
Upside: +297.11%
X4 Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $30 → $9
Current: $4.12
Upside: +118.45%
Aug 8, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $4.16
Upside: +68.27%
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $23.96
Upside: +16.86%
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $3.01
Upside: +66.11%
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $4.84
Upside: +313.22%
Mar 21, 2025
Maintains: Buy
Price Target: $240 → $100
Current: $14.38
Upside: +595.41%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.51
Upside: +164.90%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $21.92
Upside: +114.42%
Aug 20, 2024
Maintains: Buy
Price Target: $240 → $120
Current: $12.46
Upside: +863.47%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $2.73
Upside: +46.52%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $54.53
Upside: +13.70%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $1.84
Upside: +389.13%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $1.40
Upside: +757.14%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.15
Upside: +24,943.48%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.67
Upside: +686.52%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $1.66
Upside: +140.96%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $302.11
Upside: -59.29%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $71.78
Upside: -34.52%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $53.30
Upside: +104.50%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $23.69
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $7.93
Upside: +190.04%